印度于2026年生产廉价的普通类Ozempic类药品, India to produce cheap generic Ozempic-like drugs in 2026, slashing prices to $40/month.

印度计划在2026年3月专利到期后，通过生产仿制司美格鲁肽，大幅降低类似Ozempic的减肥药物成本。 India is set to slash the cost of Ozempic-like weight-loss drugs by producing generic semaglutide once its patent expires in March 2026. 至少有10家印度制药公司,包括Reddy博士、Cipla和Biocon等公司,正准备制造这种药物,这有可能将月价格降低到40美元以下。 At least 10 Indian pharmaceutical companies, including Dr. Reddy’s, Cipla, and Biocon, are preparing to manufacture the drug, potentially reducing the monthly price to as low as $40. 随着印度既有的毒品生产能力和供应87个国家的计划,这一举动可以大大增加全球获得负担得起的抗肥胖治疗的机会,特别是由于该国和全世界肥胖率上升。 With India’s established drug production capacity and plans to supply 87 countries, the move could significantly increase global access to affordable anti-obesity treatments, especially as obesity rates rise in the country and worldwide.